Interventional Care

We notice that you are visiting us from . This site only services US-based visitors. Would you like to visit the site that is appropriate for your location?
Up to 30 percent of adults are nasally colonized with S. aureus and/or MRSA. S. aureus and MRSA account for over 30% of SSIs. Nasal colonization with these bacteria increases the patient risk of developing an SSI by 9 times. To help reduce this risk, Povidone-Iodine is used as it is a broad spectrum antiseptic that has been proven effective in reducing both S. aureus and MRSA. It offers an added advantage over the widely-used nasal antibiotic, mupirocin, in that there is no known bacterial resistance to it, thereby supporting antibiotic stewardship within the healthcare environment.